Compounds > phosphotyrosine
Page last updated: 2024-08-23

phosphotyrosine and Carcinoma, Ductal, Breast

phosphotyrosine has been researched along with Carcinoma, Ductal, Breast in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Freydin, B; Hooke, JA; Hyslop, T; Klimowicz, AC; Kovatich, AJ; Liu, C; Magliocco, AM; Nevalainen, MT; Peck, AR; Pequignot, E; Rimm, DL; Rosenberg, AL; Rui, H; Sauter, G; Shriver, CD; Stringer, GA; Tran, TH; Witkiewicz, AK; Yang, N1
Attems, J; Czerwenka, K; Hudelist, G; Köstler, WJ; Kubista, E; Manavi, M; Müller, R; Singer, CF; Steger, GG; Zielinski, CC1
Heffelfinger, S; Lower, EE; Miller, MA; Westermann, C; Williams, L1
Abbondanza, C; Auricchio, F; Bilancio, A; Castoria, G; Migliaccio, A; Pagano, M1
Liu, J; Ma, Y; Spence, MJ; Streiff, R; Vestal, RE1

Other Studies

5 other study(ies) available for phosphotyrosine and Carcinoma, Ductal, Breast

ArticleYear
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Cohort Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Phosphotyrosine; Prognosis; Protein Processing, Post-Translational; STAT5 Transcription Factor; Survival Analysis; Treatment Failure; Tumor Suppressor Proteins; Young Adult

2011
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
    British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Ligands; Middle Aged; Phosphorylation; Phosphotyrosine; Prognosis; Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Progesterone; Survival Rate; Trastuzumab; Treatment Outcome

2003
Increased phosphotyrosine in breast cancer tissue is associated with a worse prognosis.
    Breast cancer research and treatment, 1995, Volume: 35, Issue:3

    Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Female; Humans; Neoplasm Staging; Phosphotyrosine; Predictive Value of Tests; Probability; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Time Factors

1995
A 67 kDa non-hormone binding estradiol receptor is present in human mammary cancers.
    International journal of cancer, 1996, Mar-01, Volume: 65, Issue:5

    Topics: Adenosine Triphosphate; Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Cytosol; Estradiol; Female; Humans; Middle Aged; Molecular Weight; Phosphotyrosine; Protein-Tyrosine Kinases; Receptor Protein-Tyrosine Kinases; Receptors, Estrogen

1996
Oncostatin M suppresses EGF-mediated protein tyrosine phosphorylation in breast cancer cells.
    Cytokine, 2000, Volume: 12, Issue:7

    Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; Culture Media; Cytokines; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Inflammation Mediators; Oncostatin M; Peptides; Phosphorylation; Phosphotyrosine; Protein Tyrosine Phosphatases; Time Factors; Tumor Cells, Cultured; Tyrosine

2000